{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:55Z","timestamp":1791357355506,"version":"4.3.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1093\/schbul\/sbq042","type":"journal-article","created":{"date-parts":[[2010,5,31]],"date-time":"2010-05-31T20:13:12Z","timestamp":1275336792000},"page":"167-177","source":"Crossref","is-referenced-by-count":215,"title":["Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons"],"prefix":"10.1093","volume":"38","author":[{"given":"Christine","family":"Rummel-Kluge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,5,31]]},"reference":[{"key":"key\n\t\t\t\t20170508185211_bib1","first-page":"329","article-title":"Clozapine: guidelines for clinical management","volume":"50","author":"Lieberman","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib2","first-page":"691","article-title":"Clozapine: an atypical antipsychotic agent","volume":"8","author":"Ereshefsky","year":"1989","journal-title":"Clin Pharmacol"},{"key":"key\n\t\t\t\t20170508185211_bib3","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004850-199803003-00009","article-title":"Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia","volume":"13","author":"Barnes","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185211_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4088\/JCP.v59n0205","article-title":"The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics","volume":"59","author":"Miller","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08r04210","article-title":"Akathisia: an updated review focusing on second-generation antipsychotics","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170508185211_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib8","volume-title":"Cochrane Schizophrenia Group in the Cochrane Library Chichester","author":"Adams","year":"2006"},{"key":"key\n\t\t\t\t20170508185211_bib9","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.5, in The Cochrane Library","author":"Higgins","year":"2005"},{"key":"key\n\t\t\t\t20170508185211_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006624","article-title":"Amisulpride versus other atypical antipsychotics for schizophrenia","volume-title":"Cochrane Database Syst","author":"Komossa"},{"key":"key\n\t\t\t\t20170508185211_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume-title":"Cochrane Database Syst","author":"Komossa"},{"key":"key\n\t\t\t\t20170508185211_bib12","article-title":"Quetiapine versus other atypical antipsychotics for schizophrenia","volume-title":"Cochrane Database Syst","author":"Komossa"},{"key":"key\n\t\t\t\t20170508185211_bib13","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia (protocol)","volume-title":"The Cochrane Library","author":"Komossa","year":"2007"},{"key":"key\n\t\t\t\t20170508185211_bib14","article-title":"Zotepine versus other atypical antipsychotics for schizophrenia","volume-title":"Cochrane Database Syst Rev","author":"Komossa"},{"key":"key\n\t\t\t\t20170508185211_bib15","first-page":"2:CD006752","article-title":"Sertindole versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170508185211_bib16","first-page":"CD006627","article-title":"Zotepine versus other atypical antipsychotics for schizophrenia","volume":"4","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170508185211_bib17","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","volume":"4","author":"Komossa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170508185211_bib18","volume-title":"Cochrane Handbook of Interventions","author":"Green","year":"2008"},{"key":"key\n\t\t\t\t20170508185211_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t20170508185211_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia","volume":"7","author":"Falkai","year":"2006","journal-title":"World J Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib21","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170508185211_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170508185211_bib23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.psychres.2006.07.012","article-title":"Anticholinergic use in hospitalised schizophrenic patients in Belgium","volume":"152","author":"De Hert","year":"2007","journal-title":"Psychiatry Res"},{"key":"key\n\t\t\t\t20170508185211_bib26","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","article-title":"Second generation antipsychotics in the treatment of acute mania: a systematic review and meta-analysis of randomized, controlled trials","volume":"64","author":"Scherk","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170508185211_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.v68n0110","article-title":"Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia","volume":"68","author":"Karow","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","article-title":"Determinants of medication compliance in schizophrenia: empirical and clinical findings","volume":"23","author":"Fenton","year":"1997","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185211_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archpsyc.1978.01770280087009","article-title":"Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point","volume":"35","author":"Van Putten","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0924-9338(99)00228-X","article-title":"Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology","volume":"14","author":"Gervin","year":"1999","journal-title":"Eur Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib34","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1176\/ajp.2006.163.8.1438","article-title":"Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study","volume":"163","author":"Tenback","year":"2006","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185211_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170508185211_bib39","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia\u2014a randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170508185211_bib40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170508185211_bib41","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second-generation antipsychotics for schizophrenia: can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychol Med"},{"key":"key\n\t\t\t\t20170508185211_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The 'atypicality' of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Grunder","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20170508185211_bib43","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2165\/0023210-200822120-00007","article-title":"Classifying antipsychotic agents: need for new terminology","volume":"22","author":"Jindal","year":"2008","journal-title":"CNS Drugs"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/38\/1\/167\/16703955\/sbq042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T14:17:19Z","timestamp":1559139439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-lookup\/doi\/10.1093\/schbul\/sbq042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,5,31]]},"published-print":{"date-parts":[[2012,1]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbq042","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.14224958.15737062","asserted-by":"object"}]},"ISSN":["1745-1701","0586-7614"],"issn-type":[{"value":"1745-1701","type":"electronic"},{"value":"0586-7614","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5,31]]}}}